March 31st 2023
Oncology nurse experts review their experiences with newcomers for the treatment of advanced endometrial cancer and exchange best practices in caring for this population.
Mirvetuximab Soravtansine Offers New Path Forward for Patients with Frα-Positive Platinum-Resistant Ovarian CancerMarch 13th 2023
Kathleen Lutz, RN, NP-BC WH, weighs in on the recent approval of mirvetuximab soravtansine-gynx for patients with folate receptor alpha (Frα)-positive, platinum-resistant ovarian cancer.
Triplet Regimen of COM701, BMS-986207, and Nivolumab Shows Antitumor Activity in Platinum-Resistant Ovarian CancerJanuary 15th 2023
Patients with heavily pretreated, platinum-resistant ovarian cancer showed promising responses with a triplet regimen consisting of COM701, BMS-986207, and nivolumab.
Rucaparib Maintenance Extends Progression-Free Survival in Advanced Ovarian CancerDecember 30th 2022
Maintenance therapy with rucaparib monotherapy improved progression-free survival compared with placebo. However, the treatment also significantly elevated anemia and neutropenia rates in this setting.
First-Line Treatments for Patients With Advanced Endometrial Cancer Who Are Unfit for SurgeryDecember 13th 2022
Kathleen Lutz, RN, NP-BC WH, explains the most commonly used first-line treatment options in patients with advanced endometrial cancer who are unsuitable candidates for surgery.
Currently Available Treatment Modalities in Endometrial CancerDecember 13th 2022
The panel reviews the current treatment modalities for endometrial cancer and in what circumstances each is considered for a patient.
Fertility and Other Treatment Considerations for Patients With Advanced Endometrial CancerDecember 7th 2022
The panel shares how they determine a treatment regimen for patients with advanced endometrial cancer taking into consideration fertility and family planning, hereditary conditions, and comorbidities.
Patient Profile Presentation: A 76-Year-Old Woman With Advanced Endometrial CancerDecember 7th 2022
Kathleen Lutz, RN, NP-BC WH, presents a 76-year-old woman with advanced endometrial cancer, and the panel assesses the chosen treatment regimens.
Cancer Has No Gender: Challenging Assumptions and Improving Quality of Care for the LGBTQ+ CommunityDecember 7th 2022
Improve care for LGBTQ+ patients with cancer by learning about disparities, focusing on patient-centered treatment, and not making assumptions about patients and their loved ones.
Zimberelimab Monotherapy Proves Safe, Effective in PD-L1–Positive Cervical CancerDecember 5th 2022
Zimberelimab demonstrated encouraging efficacy with a tolerable safety profile in patients with PD-L1–positive recurrent or metastatic cervical cancer who had progressed after first- or subsequent-line, platinum-containing chemotherapy.
Resources for Patients With Endometrial CancerNovember 29th 2022
Certified Nurse Practitioner Kimberly Spickes shares the educational and supportive resources she recommends for patients with newly-diagnosed advanced endometrial cancer.
Conversations with Patients With Advanced Endometrial Cancer Before and After DiagnosisNovember 29th 2022
Nurse Practitioners Kathleen Lutz and Kimberly Halla describe the conversations they have with patients with advanced endometrial cancer before and after diagnosis and the common questions they hear.
Initial Consultation of Patients With Advanced Endometrial Cancer
Kimberly Halla, NP, explains the staging of endometrial cancer and the standards for biomarker testing at her institution.
Symptoms and Diagnosis of Endometrial Cancer
Kimberly A. Spickes, CNP, gives an overview of the typical symptoms women with endometrial cancer present with, discusses how these symptoms are similar and different from those seen with other gynecologic malignancies, and reviews risk factors for endometrial cancer.
Mirvetuximab Soravtansine-gynx Gets Go Ahead in Platinum-Resistant Ovarian CancerNovember 15th 2022
Mirvetuximab soravtansine-gynx, an antibody drug conjugate, has received accelerated approval for platinum-resistant ovarian cancer. The prescribing label comes with warnings for visual toxicities, pneumonitis, and peripheral neuropathy.
HRD, BRCA Status May Inform PARP Inhibitor Suitability in Advanced Ovarian CancerNovember 12th 2022
During the 40th Annual Chemotherapy Foundation Symposium, Eirwen M. Miller, MD, evaluated the safety and efficacy profiles of different PARP inhibitor therapies for patients with advanced ovarian cancer.